Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
UNIVERSITETET I OSLO has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 4 distinct examiners and 4 distinct art units, showing a complete lack of concentration in the prosecution of these cases. Each of the 4 pending office actions is being handled by a different individual in a different administrative group.
The busiest examiner, ROBINSON, KYLE G, is responsible for 1 pending office action, which is consistent with the even distribution across the 4 distinct examiners. This 1 to 1 ratio of actions to examiners means that the university must manage four separate prosecution tracks simultaneously. The involvement of 4 distinct art units suggests that the 4 pending office actions cover a variety of sub-fields within Biotechnology & Pharmaceuticals.
Practitioners should be prepared for four different sets of examiner expectations and art unit guidelines. This diversity in examiners and art units prevents any single official from having a disproportionate impact on the overall portfolio. However, it also means that there is no opportunity to consolidate arguments across multiple cases with the same examiner. The 4 pending office actions require a highly individualized approach for each matter within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, KYLE G | 1 | 11.7% | +16.6% |
| DICKINSON, PAUL W | 1 | 63.2% | +9.6% |
| KUCKLA, ANNA GRACE | 1 | 53.8% | +51.3% |
| JOHANSEN, PETER N. | 1 | 59.6% | +24.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19131342 | ASSESSING HEALTH OF A HEART VALVE | ROBINSON, KYLE G | — |
| 18033911 | PHOSPHATE BASED TARGETS | DICKINSON, PAUL W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002800 | USES, METHODS AND PRODUCTS RELATING TO OLIGOMERIC LIPOPOLYSACCHARIDE BINDING PROTEINS | JOHANSEN, PETER N. | 26d |
| 19131342 | ASSESSING HEALTH OF A HEART VALVE | ROBINSON, KYLE G | — |
| 18247498 | TREATMENT FOR VIRAL INFECTION | KUCKLA, ANNA GRACE | — |
| Art Unit | Apps |
|---|---|
| 3685 | 1 |
| 1618 | 1 |
| 1626 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19131342 | ASSESSING HEALTH OF A HEART VALVE | ROBINSON, KYLE G | 3685 | §101§102§103§112 | Non-Final OA | — | Pending | May 20, 2025 |
| 18033911 | PHOSPHATE BASED TARGETS | DICKINSON, PAUL W | 1618 | §103§112 | Non-Final OA | — | Pending | Apr 26, 2023 |
| 18247498 | TREATMENT FOR VIRAL INFECTION | KUCKLA, ANNA GRACE | 1626 | §103 | Final Rejection | — | Pending | Mar 31, 2023 |
| 18002800 | USES, METHODS AND PRODUCTS RELATING TO OLIGOMERIC LIPOPOLYSACCHARIDE BINDING PROTEINS | JOHANSEN, PETER N. | 1644 | §112 | Final Rejection | 26d | Pending | Dec 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITETET I OSLO has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Kyle G Robinson has the most, with 1 of UNIVERSITETET I OSLO's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
